ADMA Biologics
ADMA
95 hedge funds and large institutions have $143M invested in ADMA Biologics in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 16 closing their positions.
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
4% more funds holding
Funds holding: 91 → 95 (+4)
9% more capital inflows, than outflows
Capital inflows: $12.2M | Capital outflows: $11.3M
0.4% more ownership
Funds ownership: 56.11% → 56.51% (+0.4%)
13% less call options, than puts
Call options by funds: $1.42M | Put options by funds: $1.63M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.32M |
| 2 |
BlackRock
New York
|
+$1.21M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.19M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$842K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$841K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Laurion Capital Management
New York
|
-$2.53M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$2.08M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$1.11M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$722K |
| 5 |
Magnetar Financial
Evanston,
Illinois
|
-$720K |
ADMA Hedge Fund Activity: Q2 2020 in Review
95 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2020, worth a combined $143M — up 2.5% from $140M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ADMA positions and 16 closed out — a net gain of 4 holders — while 32 added to existing stakes and 27 trimmed.
The largest buyer was Essex Investment Management, opening a new position worth an estimated $1.32M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $2.53M sold.
- 95 institutional investors held ADMA Biologics (ADMA) as of Q2 2020, up from 91 in Q1 2020.
- Funds reported $143M of ADMA Biologics stock for Q2 2020, up 2.5% quarter-over-quarter.
- 20 funds opened new ADMA Biologics positions in Q2 2020 and 16 closed out, a net change of +4 holders.
- The largest ADMA Biologics buyer in Q2 2020 was Essex Investment Management, an estimated $1.32M added.
- The largest ADMA Biologics seller in Q2 2020 was Laurion Capital Management, an estimated $2.53M sold.
Based on aggregated 13F filings for Q2 2020.